A Costa Rican research agency that has run the HPV vaccine trials in Guanacaste with the US National Cancer Institute, including the trial that found one dose of HPV vaccine as good as two.
The Agencia Costarricense de Investigaciones Biomédicas, linked with the Fundación INCIENSA, is the Costa Rican partner in the HPV vaccine studies run with the US National Cancer Institute's Division of Cancer Epidemiology and Genetics. ClinicalTrials.gov lists its site in Liberia, Guanacaste, for ESCUDDO (NCT03180034), the NCI-sponsored trial with the Gates Foundation as collaborator that randomised 20,330 girls aged 12 to 16 to one or two doses of a bivalent or nonavalent HPV vaccine and found one dose noninferior to two. Its researchers are authors of the Costa Rica Vaccine Trial of 7,466 women enrolled in 2004 and 2005, of PRIMAVERA in Guanacaste, and of PRISMA, a trial of single-dose vaccination in 4,925 women aged 18 to 30. Papers give its address as San José; the coordinates are an approximate point for Liberia, where the trials are run.
The Ministry of Health said in December 2023 that the agency had contributed two medical records staff to help bring the national cancer registry up to date.
Antibody levels alone did not meet the bar for changing the vaccine's label to one dose, which is why trials measuring protection directly, such as ESCUDDO, were needed.
One dose of HPV vaccine protected girls against infection with HPV 16 and 18, the two types that cause most cervical cancers, as well as two doses did, so the same supply of vaccine could protect more girls.
Protection from the bivalent HPV vaccine against the precancers that lead to cervical cancer lasted more than a decade.
Shares Gates Foundation, Cervical cancer.
Shares Gates Foundation, Cervical cancer.
Shares HPV bivalent vaccine (types 16 and 18), Nonavalent HPV vaccine, Cervical cancer.
Shares HPV bivalent vaccine (types 16 and 18), Cervical cancer.
Shares HPV bivalent vaccine (types 16 and 18), Cervical cancer.
Shares Nonavalent HPV vaccine, National Cancer Institute (NIH), Cervical cancer.
Shares Gates Foundation, Cervical cancer.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/